H.C. Wainwright Adjusts Ikena Oncology Stock Target Following Halt of IK-930 Trial
Wednesday, 29 May 2024, 09:35
H.C. Wainwright Lowers Ikena Oncology Shares Target
H.C. Wainwright has adjusted the target price for Ikena Oncology shares following the suspension of the IK-930 trial.
Reason for Adjustment
The halt in the clinical trial has led the financial firm to reassess the performance outlook for Ikena Oncology.
Investor Recommendation
- Investors are advised to stay informed about the latest updates regarding the trial suspension.
- Closely monitor Ikena Oncology's stock performance in the coming days.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.